Invests primarily in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs. Now — the numbers.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
It pays out $1.68 per share each year — regular cash for whoever holds the stock.
The price action doesn’t yet back an upward turn.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.